Category - Executive Moves

Executive Moves

Jim Lilly joins England & Co. in healthcare investment banking

Jim Lilly joined England & Co., a middle-market investment bank, as a managing director in its New York office. Mr. Lilly brings more than 30 years of experience as a strategic advisor to a wide variety of...

January 19, 2021

Executive Moves

Justin Zelin joins BTIG as biotech analyst

BTIG has expanded its healthcare research coverage, adding Justin Zelin to its research and strategy division as a director. His biotech research coverage will include cell therapy, targeted oncology, immunology and...

January 15, 2021

Executive Moves

IntelGenx names Tommy Kenny as VP of intellectual property and legal affairs, general counsel

IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) appointed Tommy Kenny as VP intellectual property and legal affairs, general counsel of IntelGenx Corp., the company’s operating subsidiary. Mr. Kenny has been with...

January 13, 2021

Executive Moves

Fibrocor Therapeutics names biotech veteran Joseph Walewicz as CFO

Closely-held Fibrocor Therapeutics appointed Joseph Walewicz, a biotech veteran with more than 25 years of experience in finance, capital markets and business development, as CFO. Prior to joining Fibrocor, Mr. Walewicz...

January 7, 2021

Executive Moves

iBio names renowned drug discovery and development expert Martin Brenner as CSO

iBio (NYSE American:IBIO) appointed Martin Brenner, Doctor of Veterinary Medicine, Ph.D., as chief scientific officer, effective Jan. 18, 2021. Dr. Brenner has a strong history of success heading drug discovery and...

December 28, 2020

Executive Moves

PDS Biotechnology names Seth Van Voorhees as CFO

PDS Biotechnology (NASDAQ:PDSB) appointed Seth Van Voorhees, Ph.D., as its new CFO, effective Jan. 1, 2021. He replaces Michael King, who served as interim CFO. Dr. Van Voorhees most recently was CFO of Research...

December 9, 2020

Executive Moves

Benjamin Bowen joins Roth’s healthcare investment banking team

Benjamin Bowen, Ph.D., has joined Roth Capital Partners as managing director, healthcare investment banking. Prior to joining Roth, Dr. Bowen most recently was managing director in the investment banking group at...

December 4, 2020

Executive Moves

Profound Medical appoints accomplished financial executive, Murielle Lortie, to board

Profound Medical (NASDAQ:PROF; TSX:PRN) appointed financial executive, Murielle Lortie, as a director, effective immediately. Ms. Lortie is the CFO of Liminal Biosciences, a Nasdaq-listed, clinical-stage...

November 30, 2020

Executive Moves

ObsEva names Brian O’Callaghan as CEO

ObsEva (NASDAQ:OBSV) appointed Brian O’Callaghan as CEO, effective Dec. 1. He succeeds ObsEva’s co-founder, Ernest Loumaye, M.D., Ph.D., who is retiring from his role as CEO but will remain a director of the company. Mr...

November 9, 2020

Executive Moves

Marizyme names Neil Campbell as president and CEO

Marizyme (NASDAQ:MRZM) appointed Neil Campbell, Ph.D., as CEO, replacing executive chairman James Sapirstein, who has been the company’s interim CEO since September 2020. Dr. Campbell currently serves as chairman of...

November 6, 2020

Category - Executive Moves

Jim Lilly joins England & Co. in healthcare investment banking

Justin Zelin joins BTIG as biotech analyst

IntelGenx names Tommy Kenny as VP of intellectual property and legal affairs, general counsel

Fibrocor Therapeutics names biotech veteran Joseph Walewicz as CFO

iBio names renowned drug discovery and development expert Martin Brenner as CSO

PDS Biotechnology names Seth Van Voorhees as CFO

Benjamin Bowen joins Roth’s healthcare investment banking team

Profound Medical appoints accomplished financial executive, Murielle Lortie, to board

ObsEva names Brian O’Callaghan as CEO

Marizyme names Neil Campbell as president and CEO

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter